Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company. With a market cap of $97.9 billion, the company engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products. 

Companies worth $10 billion or more are generally described as “large-cap stocks”, and Bristol-Myers Squibb fits this description perfectly. The company portfolio includes key therapies in oncology, immunology, cardiovascular, and hematology. It also continues to expand its pipeline through internal R&D and strategic acquisitions.

Shares of Bristol-Myers Squibb have dipped 24.1% from its 52-week high of $63.33. BMY stock has fallen 19.7% over the past three months, lagging behind the iShares Global Healthcare ETF’s (IXJ) 8.4% decrease.

On a YTD basis, Bristol-Myers Squibb stock has crumbled nearly 15%, underperforming IXJ’s marginal decline. However, over the past 52 weeks, shares of BMY have soared 15.1%, significantly outperforming the IXJ's 7.3% drop.

Despite some fluctuations, the stock has been trading mostly below its 50-day and 200-day moving averages since early April.

BMY stock rose marginally following the release of its Q1 2025 results on Apr. 24. While, the company reported revenue of $11.2 billion, marking a decline of 5.6% year-over-year from the prior-year quarter, its adjusted EPS came in at $1.80 compared to the loss of $4.40 per share in the year-ago quarter. Looking ahead to fiscal 2025, the company has raised its guidance and now expects revenue to be in the range of $45.8 billion to $46.8 billion, and adjusted EPS is projected to be in the range of $6.70 to $7. 

Moreover, the stock rose 1.1% on Jun. 2 after announcing a global co-development and co-commercialization deal with Bristol Myers Squibb for its bispecific antibody BNT327. The agreement targets multiple solid tumors and includes a $1.5 billion upfront payment from BMY to BioNTech.

In contrast, rival AbbVie Inc. (ABBV) has outpaced BMY stock. Shares of AbbVie have climbed 16.9% over the past 52 weeks and a 5.4% rise on a YTD basis.

Despite the stock’s outperformance relative to the sector over the past year, analysts are cautiously optimistic on BMY. The stock has a consensus rating of “Moderate Buy” from the 26 analysts covering the stock and, as of writing, is trading below the mean price target of $56.14.